Search - tctmd.com

Displaying 21 - 34 of 34

Sort: Relevancy | Date

News Opinion CV Team Dispatch

May 2024 Dispatch for the CV Team

L.A. McKeown

May 01, 2024

Podcast Heart Sounds

April 2024: Key Takeaways From ACC 2024

April 24, 2024

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

Podcast TCTMD Talking Points

The ORBITA-2 Trial

April 03, 2024

News Opinion Editor's Corner ACC 2024

What’s Going to Be Hot at ACC 2024

Shelley Wood

April 01, 2024

News Daily News

Real-life Patients Do Well With Intravascular Lithotripsy: Spanish Registry

Caitlin E. Cox

March 01, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

Presentation CTO 2024

Should ORBITA2 Change How I Think About CTO PCI?

Presenter: Robert W. Yeh

February 02, 2024

News Features

A Sham-Controlled Trial of AF Ablation Is Feasible, but Is It Needed?

Todd Neale

January 25, 2024

News Opinion Editor's Corner

The Biggest News of 2023: TCTMD’s Top 10

Shelley Wood

January 01, 2024

Video

» Interview

Beyond the Data: ORBITA-COSMIC

April 15, 2024

Partner Content

Expanding Treatment Options for Calcium Management

April 10, 2024

Advertisement

May 2024 Dispatch for the CV Team

April 2024: Key Takeaways From ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

The ORBITA-2 Trial

What’s Going to Be Hot at ACC 2024

Real-life Patients Do Well With Intravascular Lithotripsy: Spanish Registry

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Should ORBITA2 Change How I Think About CTO PCI?

A Sham-Controlled Trial of AF Ablation Is Feasible, but Is It Needed?

The Biggest News of 2023: TCTMD’s Top 10

Beyond the Data: ORBITA-COSMIC

Expanding Treatment Options for Calcium Management

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content